Pharmabiz

Argo Biopharma begins patient dosing in phase II trials of siRNA therapy BW-40202

Argo Biopharma begins patient dosing in phase II trials of siRNA therapy BW-40202: Shanghai, China Wednesday, April 22, 2026, 15:00 Hrs [IST] Argo Biopharmaceutical Co., Ltd. (Arg ...
Pharmabiz

Boehringer Ingelheim expands investment in computational innovation with new AI accelerator in UK’s Knowledge Quarter

Boehringer Ingelheim expands investment in computational innovation with new AI accelerator in UK’s Knowledge Quarter: ...
Pharmabiz

Merck unveils first bio-based solvent portfolio for high-performance liquid chromatography

Merck, a leading science and technology company, has launched the first bio-based solvent portfolio specifically for high-performance liquid chromatography (HPLC). Manufactured using renewable ...
Pharmabiz

Merck and Eisai provide update on phase 3 LITESPARK-012 trial evaluating first-line combination treatments for certain patients with advanced RCC

Merck and Eisai provide update on phase 3 LITESPARK-012 trial evaluating first-line combination treatments for certain patients with advanced RCC: Rahway, New Jersey Wednesday, Ap ...
Pharmabiz

Integrated DNA Technologies expands Coralville manufacturing footprint to support global demand for minimal residual disease solutions

Integrated DNA Technologies expands Coralville manufacturing footprint to support global demand for minimal residual disease solutions: Coralville, Iowa Wednesday, April 22, 2026, ...
Pharmabiz

Jaslok Hospital launches clinical study to enable AI-based prediction of Parkinson’s freezing episodes

Jaslok Hospital launches clinical study to enable AI-based prediction of Parkinson’s freezing episodes: Our Bureau, Mumbai ...
Pharmabiz

HCL Healthcare deepens Bengaluru presence with Central Regional Office, enhances accessibility for enterprise clients

HCL Healthcare deepens Bengaluru presence with Central Regional Office, enhances accessibility for enterprise clients: Our Bureau, Bengaluru Wednesday, April 22, 2026, 11:30 Hrs [ ...
Pharmabiz

Dana-Farber Cancer Institute’s study shows predictive value of Ignite Proteomics’ RPPA platform for Enhertu therapy in metastatic breast cancer

Dana-Farber Cancer Institute’s study shows predictive value of Ignite Proteomics’ RPPA platform for Enhertu therapy in metastatic breast cancer: Mountain View, California Wedn ...
Pharmabiz

Ultomiris demonstrated statistically significant and clinically meaningful reduction of proteinuria in adults with IgAN in I CAN phase III trial

Positive high-level results from a prespecified interim analysis of the I CAN phase III trial showed that Ultomiris (ravulizumab) met its primary endpoint, demonstrating a statistically significant ...
Pharmabiz

Health ministry amends recruitment rules for DCGI

Our Bureau, New Delhi Wednesday, April 22, 2026, 09:15 Hrs [IST] The Union ministry of health and family welfare has amended the ...
Pharmabiz

US FDA accepts Roche’s sBLA for Gazyva/Gazyvaro for the treatment of systemic lupus erythematosus

US FDA accepts Roche’s sBLA for Gazyva/Gazyvaro for the treatment of systemic lupus erythematosus: Basel Wednesday, April 22, 2026, 09:00 Hrs [IST] Roche announced that the US F ...
Pharmabiz

Indian healthcare sector faces escalating cyber risks as complex hospital IT systems widen attack surface

Indian healthcare sector faces escalating cyber risks as complex hospital IT systems widen attack surface: Nandita Vijayasimha, Bengaluru Wednesday, April 22, 2026, 08:00 Hrs [IST ...